β2-adrenergic receptor functionality and genotype in two different models of chronic inflammatory disease: Liver cirrhosis and osteoarthritis

REYES ROCA1, PABLO ESTEBAN1, PEDRO ZAPATER2,3, MARÍA-DEL-MAR INDA4, ANNA LUCIA CONTE1, LAURA GÓMEZ-ESCOLAR5, HELENA MARTÍNEZ6, JOSÉ F. HORGÁ3, JOSÉ M. PALAZÓN5 and ANA M. PEIRÓ3,4

1Occupational Observatory, Miguel Hernández University (UMH) of Elche, 03202 Elche; 2CIBERehd, Carlos III Health Institute, 28029 Madrid; 3Clinical Pharmacology, General Hospital of Alicante; 4Neuropharmacology on Pain (NED) Research Group, ISABIAL-FISABIO, General Hospital of Alicante; 5Liver Unit, General Hospital of Alicante, 03010 Alicante; 6Clinical R&D Area, Bioiberica S.A., 08029 Barcelona, Spain

Received June 12, 2017; Accepted September 28, 2017

DOI: 10.3892/mmr.2018.8820

Abstract. The present study was designed to investigate the functional status of β2 adreceptors (β2AR) in two models of chronic inflammatory disease: Liver cirrhosis (LC) and osteoarthritis (OA). The β2AR gene contains three single nucleotide polymorphisms at amino acid positions 16, 27 and 164. The aim of the present study was to investigate the potential influence of lymphocyte β2AR receptor functionality and genotype in LC and OA patients. Blood samples from cirrhotic patients (n=52, hepatic venous pressure gradient 13±4 mmHg, CHILD 7±2 and MELD 11±4 scores), OA patients (n=30, 84% Kellgren-Lawrence severity 4 grade, 14% knee replacement joint) and healthy volunteers as control group (n=26) were analyzed. Peripheral blood mononuclear cells (PBMC) were isolated from whole blood and basal and isoproterenol induced adenylate cyclase activity (isoproterenol stimulus from 10−9 to 10−4 mM), and β2AR allelic variants (rs1042713, rs1042714, rs1800888) were determined. β2AR functionality was decreased in the two different models of chronic inflammatory disease studied, OA (50% vs. control) and LC (85% vs. control). In these patients, the strength of the β2AR response to adrenergic stimulation was very limited. Adrenergic modulation of PBMC function through the β2AR stimulus is decreased in chronic inflammatory processes including LC and OA, suggesting that the adrenergic system may be important in the development of these processes.

Introduction

The role of the sympathetic nervous system (SNS) in inflammation is still not completely understood, although it is well known that disturbed interaction between both contributes to pathogenic chronic inflammatory diseases (1,2). Evidence for the possibility of such interaction have been reinforced since the discovery of the expression of beta-2-adrenergic receptor (β2AR) on T and B lymphocytes, macrophages, natural killer cells and neutrophils (3-6). Coexistence of all β adrenoceptors (βAR) subtypes has been reported in human peripheral blood mononuclear cells (PBMC) and erythrocytes (7), but lymphocyte β1AR and β3AR functionality in these cells has not been evidenced yet (8,9). Stimulation of PBMC β2AR by catecholamines or selective pharmacologic ligands differentially regulates activity depending on cell activation and differentiation state, molecular signalling pathway and cytokine microenvironment.

Since β2AR activity on circulating mononuclear cells is related to the level of β2AR activity on solid tissues cells, such as heart and skeletal muscle, mononuclear cells could be used as markers to evaluate development and progression of systemic β2AR (10). Recent studies suggested that β2AR modulation could be relevant in the development of joint diseases as rheumatoid arthritis (RA) (11-14), adjuvant-induced arthritic (AA) (15), and immune hepatitis (16,17). Thus, two different models of chronic inflammatory diseases were selected (osteoarthritis (OA) and liver cirrhosis (LC)) to study the potential relation between their progression and PBMC β2AR functionality and genotype.

OA is the most common articular disorder characterized by chronic inflammation of the joint lining. Although OA inherently lacks the large scale systemic inflammatory response that is a hallmark in rheumatoid arthritis (RA), this is suggestive of low activation grade. In OA, the innervation pattern of sympathetic and sensory nerve fibres is altered in adult joint tissues and bone (18). It is now believed that synovial inflammatory changes in OA are associated with massive destruction of capillary and neuronal network with preponderance of...
sympathetic over sensory fibres. This promotes an increase in articular vessels adrenoceptor type towards β2AR (19.20). Osteoblasts, osteoclasts, mesenchymal stem cells, synovial fibroblasts, and different types of chondrocytes produce distinct subtypes of adrenoceptors, receptors for vasointestinal peptide, for substance P and calcitonin gene-related peptide. Even more, cartilage integrity is maintained by a balance from cytokine-driven anabolic and catabolic processes (21). In fact, a novel OA treatment consists in the use of biological molecules with antiinflammatory properties (22,23).

Cirrhosis causes 90% of portal hypertension in the Western world. This in turn triggers the formation of varices which are present in 30% of patients with compensated cirrhosis and 60% of those with decompensated cirrhosis (24). In an attempt to maintain effective circulating volume, endogenous vasoconstrictor systems as adrenergic are recruited. Adrenergic system releases catecholamines as adrenaline, which binds to α (vasoconstrictor) and β (vasodilator) adrenoceptors. Engagement of the β2AR activates a cascade of signalling intermediates, including cAMP and protein kinase A, leading to the phosphorylation of cellular proteins including transcription factors that mediate metabolic processes and gene expression (25). Currently the most widely used modalities to prevent variceal bleeding in LC patients are drugs as propranolol, a non-selective beta-blocker (26-28). However, the prevalence of patients ‘non-responders’ ranges between 30 and 60%, suggesting changes in the functional state of βAR receptors (29).

An interesting possibility is that underlying genetic β2AR variability is involved in participant's efficacy of beta-blockers treatment (30). Three functionally relevant β2AR gene single-nucleotide polymorphisms (SNPs) (Arg16Gly, rs1042713; Glu27Glu, rs1042714; Thr164Ile, rs1800888) have been associated with joint disorder, functional gastrointestinal disorders playing an important role in vascular regulation (31-34) and bronchial smooth muscle tone (35). In particular, Glu27Glu variant is associated with bone health (36), RA (37,38), functional gastrointestinal diagnoses and bowel symptoms severity (39).

We analyzed β2AR functionality and genotype (rs1042713, rs1042714, rs1800888) in PBMC in patients diagnosed with OA and LC.

Materials and methods

Patients. A total of 30 OA and 52 LC patients, together with 26 healthy volunteers participated in the study. Blood samples were drawn from antecubital vein in the morning.

Ethical approval. Protocol was approved by the Clinical Research Ethics Committee of Alicante Department of Health, General Hospital (Alicante, Spain). All participants signed informed consent before enrolment, and the study was performed according to the Declaration of Helsinki.

OA patients. Patients from Primary Care of Alicante General Hospital Department of Health with knee OA were included in this study.

The inclusion criteria were as follows: Ages ranging from 50 to 80 years; diagnosis of knee OA according to the criteria established by the American College of Rheumatology (ACR) using history, physical examination and radiographic findings, knee X-rays in the last 12 months and a Kellgren-Lawrence (KL) OA grade of 2 or more, based on the radiological severity (grade 1, questionable narrowing of joint space and possible osteophyte lipping; grade 2, definite osteophytes and possible narrowing of joint space; grade 3, moderate multiple osteophytes, definite narrowing of joints space, some sclerosis, and possible deformity of bone contour; and, grade 4, large osteophytes, marked narrowing of joint space, severe sclerosis, and definite deformity of bone contour) (40).

Patients with infections, inflammatory diseases, malignancies or patients using α- or β-adrenergic receptor agonists or antagonists were excluded from the study.

Cirrhotic patients. Patients from Liver Unit of Alicante Department of Health, General Hospital with LC were included in this study.

The inclusion criteria were as follows: Ages ranging from 40 to 80 years; diagnosis of cirrhosis according to the criteria established by Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Center for Liver and Digestive Diseases (CIBERehd) (41): Either liver biopsy or unequivocal clinical, imaging and biochemical findings (e.g., complete blood cell count, serum chemistries, liver function test, and coagulation studies).

None of the patients had an established transjugular intrahepatic portosystemic shunt (TIPS). Patients with systolic blood pressure <100 mmHg bradycardia (heart rate <50/min), obstructive airway disease or other contraindications for treatment with propranolol were excluded from the study.

Patients were classified in two groups: Under prophylaxis or treatment of first upper gastrointestinal bleeding episode (‘primary prophylaxis’) or prophylaxis of recurrent bleeding (‘secondary prophylaxis’). As non-bleeding varices are generally asymptomatic, high hepatic venous pressure gradient (HVPG) is the clinical gold standard for risk of formation prediction (>12 mmHg) or rebleeding (HVPG >20 mmHg) and to predict the response to β blocker antagonists during treatment of portal hypertension (>20% fall from baseline of portal pressure). Hence HVPG clinical routinely monitoring allow the identification of patients who will be effectively protected against the risk of bleeding (labeled as ‘responder’) and those who, by not achieving a HVPG reduction by 20% of baseline or to ≤12 mmHg, present a very high risk of bleeding (‘non-responders’). LC patients clinical data is presented in Table I.

In patients with previous variceal bleeding, investigations were made at least 7 days after the complete recovery of bleeding.

Controls subjects. A total of 26 healthy controls were recruited through blood donors from the same geographical areas as patients, and were matched to patients according ethnicity (at least 2 generations from the same area). None of the subjects in the healthy control group had any clinically significant abnormality shown by routine history, physical examination, or laboratory tests.

Determination of basal and stimulated intracellular cAMP. PBMC were isolated from EDTA venous blood by Percoll density gradient centrifugation. Activation of β2AR leading
to an increase in the intracellular level of cyclic adenosine monophosphate (cAMP, pmol/ml/10^6 cells) by increasing adenylate-cyclase (AC) activity was evaluated in duplicates by cAMP determination using a competitive Enzyme Immunoassay (EIA) according to laboratory procedures and manufacturer guidelines (Cayman Chemical Company, Ann Arbor, MI, USA).

Cells were counted in a Coulter Counter and with a Neubauer chamber. Viability was determined by trypan blue exclusion and ranged between 94-98%. Cells were incubated as described by Sondergaard et al. (42). Aliquots of 1x10^6 PBMC were rinsed with Phosphate-buffered saline (1x PBS, pH 7.4, containing 135 mM NaCl, 5.4 mM KCl, 1.4 mM MgSO_4_, 1.4 mM CaCl_2, 0.18 mM sodium phosphate) and 3% (wt/vol) of bovine serum albumin (BSA fraction V (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) (PBS-BSA) at room temperature. Phosphodiesterases were inhibited by preincubation at 37˚C for 30 min with 1 mM isobutyl-3-methyl-xanthine (IBMX) (Sigma-Aldrich; Merck KGaA). Then, cells were stimulated with different concentrations of isoproterenol (ISO) ranging from 10^-9 to 10^-4 mM or vehicle for 15 min. Stimulation was stopped at 100˚C water bath for 3 min. Samples were centrifuged for 5 min at 3500 rpm and disrupted by sonication 3x15 sec (model SM25E-MT; Branson Ultrasound Corporation, Geneva, Switzerland). Lysates were immediately frozen and stored at -80˚C until EIA analysis was performed as described previously.

On the day of the assay, samples were thawed at room temperature for 25-30 min and centrifuged at 4˚C at 3,500 rpm for 10 min to remove insoluble material. cAMP was measured in the supernatant using a EIA. cAMP increase was calculated by subtraction of values determined in IBMX preincubated samples. All assays were performed in duplicate.

DNA extraction and beta-adrenergic genotyping. Blood samples from OA and LC patients and healthy controls were collected and genomic DNA was extracted from isolated PBMC using QIAamp® DNA Midi Kit according to manufacturer’s instructions.

Genomic DNA was genotyped for SNPs within the β2AR gene locus. Three SNPs with high frequency of polymorphism in the human population (>20% prevalence) and located within the coding region for gene were chosen. The known functional SNP rs1042713, rs1042714 and rs1800888 are well-studied common non-synonymous SNPs (43,44).

β2AR genotype at positions 16, 27 and 164 was determined by polymerase chain reaction (PCR) and sequenced by Thermosequenase Primer Cycle kit (Amersham Pharmacia Biotechnology, Piscataway, NJ, USA). PCR was performed in a final volume of 25 µl containing 100-200 ng DNA, 0.2 mM of each dNTP, 1X de reaction buffer (50 mM KCl and 20 mM Tris-HCl, pH 8.4), 1.5 mM MgCl_2, 1 U Taq DNA polymerase, 10% DMSO and 200 nM of each primer. Temperature cycling was 94˚C for 30 sec, 61˚C for 45 sec, and 72˚C for 45 sec for 30 cycles. In total, 10 µl of the PCR products were visualized on a 1% agarose gel stained with ethidium bromide. Computer analysis of all SNP combinations in the human EST database (dbEST release 030405, 6,053,112 human entries) was performed using BLAST (National Library of Medicine, Bethesda, MD, USA). Complete nucleotide sequence of β2AR gene was used (NM 000024) to design the primers (Primer 3; UCSD, San Diego, CA, USA).

Western blotting. To determine whether cAMP concentration changes in PBMC from patients was associated with variations in immunodetectable β2AR protein, quantitative Western blotting analysis was performed.

Table I. Cirrhotic patient's demographic and clinical data.

<table>
<thead>
<tr>
<th>Clinical data</th>
<th>Cirrhotic primary (n=22)</th>
<th>Cirrhotic secondary (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascites (yes/no)</td>
<td>5/17</td>
<td>14/17</td>
</tr>
<tr>
<td>HDA</td>
<td>2/20</td>
<td>27/3</td>
</tr>
<tr>
<td>Previous treatment with beta-blockers (yes/no)</td>
<td>2/20</td>
<td>16/14</td>
</tr>
<tr>
<td>Total bilirubin (mg/dl)</td>
<td>1,31±0.9</td>
<td>1,64±0.8</td>
</tr>
<tr>
<td>Serum albumin (g/dl)</td>
<td>3,49±0.7</td>
<td>3,18±0.4</td>
</tr>
<tr>
<td>Quick (%)</td>
<td>76±16</td>
<td>68±14</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>0.9±0.4</td>
<td>0.8±0.2</td>
</tr>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>13.02±2.1</td>
<td>11.75±2.2</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td>39±6</td>
<td>36±6</td>
</tr>
<tr>
<td>Platelets (10^9/mm³)</td>
<td>102±58</td>
<td>91±51</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>113±51</td>
<td>106±28</td>
</tr>
<tr>
<td>Systolic arterial pressure (mmHg)</td>
<td>128.0±17.7</td>
<td>130.2±18.7</td>
</tr>
<tr>
<td>Diastolic arterial pressure (mmHg)</td>
<td>81.7±10.7</td>
<td>77.2±12.2</td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>74.6±16.6</td>
<td>74.5±11.3</td>
</tr>
<tr>
<td>Wedged hepatic venous pressure (mmHg)</td>
<td>22.9±5.4</td>
<td>25.4±4.2</td>
</tr>
<tr>
<td>Free hepatic venous pressure (mmHg)</td>
<td>8.1±3.8</td>
<td>8.8±3.7</td>
</tr>
<tr>
<td>Hepatic venous pressure gradient pre (mmHg)</td>
<td>15±4.9</td>
<td>17±3.3</td>
</tr>
<tr>
<td>Hepatic venous pressure gradient post (mmHg)</td>
<td>12±3.6</td>
<td>15±4.3</td>
</tr>
</tbody>
</table>
After treatment with isoproterenol, cells were lysed and protein was extracted using RIPA buffer (50 mM Tris-HCl pH 7.4; 150 mM NaCl, 1 mM EDTA, 0.25% Na-deoxycholate, 1% NP-40, 1 mM PMSF, 1 mM sodium orthovanadate, 1 µg/ml leupeptin, 1 µg/ml aprotinin, and 1 µg/ml pepstatin). Protein concentration was determined by BCA assay and samples were separated on 12% SDS-PAGE gels, and transferred onto Hybond-enhanced chemiluminescence (ECL) nitrocellulose membranes. Membranes were probed with antibodies against β2AR (R11E1, sc-81577; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) of human origin. Protein bands were observed using ECL and specific bands were detected with X-film according to procedures of Proteomics and Genomics Division, Research Technical Facility of University of Alicante (Alicante, Spain).

Spot detection and quantification was performed using Progenesis Same Spots software according to manufacturer’s instructions (Nonlinear USA., Inc., Durham, NC, USA). Two individual gel replicates from each subject were used for the analysis. Results were expressed as relative arbitrary units (AU) according to procedure previously described (45), using as standard samples from 4 healthy subjects. GAPDH was used as endogenous control.

Statistical analysis. Quantitative data is expressed as mean ± standard deviation (SD). Differences between groups were analysed using the T-Student or non-parametric Mann-Whitney U-test according to normality. Qualitative variables are expressed as frequency or percentage and differences between groups were evaluated using χ² test. A comparison of independent single variables between the groups was calculated by one way analysis of variance (ANOVA) followed by Turkey’s procedure. When normality test failed, Kruskal-Wallis one-way ANOVA on ranks was used. A two-tailed P<0.05 was considered to indicate a statistically significant difference.

Results

Patients and control subjects. Thirty OA patients (age, 70±8 years; female, 78%; median (min, max) OA duration, 6 (1-29) years) were included in this study. A total of 12% were diabetic, 14% hypertensive, 8% dislipemic and 9% BMI >30 kg/m². Mainly category of KL radiological severity was 3-4 (90%) grades and 15 (54%) patients required knee joint replacement (76% KL grade 4). Regular current use of analgesic (acetaminophen, dipyromine), and non-steroidal anti-inflammatory drugs (NSAIDs: Ibuprofen, naproxen or celecoxib) was very common (21 and 50%, respectively), followed by chondroitin sulphate (12%), glucosamine (6%) and tramadol (2%).

A total of 52 LC patients (age, 54±11 years; females, 13.5%) were submitted to the hospital clinic for HVPG determination and were included in the study. Alcohol was actively consumed by 11.5% of patients. Scores for Model for End-stage Liver Disease (MELD) were 11±4 and Child-Pugh 7±2, respectively. In total, 37% patients were previously treated with beta-blockers and 50% exhibited clinical response to propranolol (46).

A total of 26 healthy human volunteers (aged 59±13 years; female 50%) participated in the present study. They had normal blood cell counts, normal liver and kidney function test results, and normal findings on physical examination.

Basal and stimulated intracellular cAMP. PBMC from control group stimulated with different concentrations of isopropenol (10⁻⁹ to 10⁻⁴ M), showed a significant increase in cAMP production in a dose-dependent manner with a maximum response between 10⁻⁵ to 10⁻⁴ M (Fig. 1A and B), Isopropenol induced a significantly lower increase in cAMP concentration in OA and LC patients (44±28 and 14±15.5 pmol/ml/10⁶ cells respectively) vs. controls (90±66 pmol/ml/10⁶ cells, P<0001) at isopropenol 10⁻⁵ M stimulus (Fig. 1A and B, respectively).

OA patients with severity KL grade 4 (n=17) presented a smaller response than lower KL severity grades (n=6) (38±21 and 61±42 pmol/ml/10⁶ cells at isopropenol 10⁻⁵ M stimulus, respectively, P=0.06) (Fig. 1A). We observed a relevant (67%) and significant reduction in cAMP increase in KL grade 4 with knee replacement patients (n=12) compared with non-surgery patients (n=5) (30±14 vs. 52±23 pmol/ml/10⁶ cells, respectively, P=0.046).

Cirrhotic patients have a significant decreased in β2AR-mediated AC activity stimulation, similar in patients with primary or secondary prophylaxis and in responder or non-responder cirrhotic patients (Fig. 1B).
Table II. Polymorphisms and allele frequencies of $\beta_{2}$AR genotype analyzed.

<table>
<thead>
<tr>
<th>SNP</th>
<th>Control</th>
<th>Osteoarthritis</th>
<th>Liver cirrhosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Naïve joint replacement</td>
<td>Knee joint replacement</td>
<td>Total</td>
</tr>
<tr>
<td>Gly16Arg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>19 (73%)</td>
<td>10 (76%)</td>
<td>9 (64%)</td>
</tr>
<tr>
<td>GA</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>GG</td>
<td>7 (27%)</td>
<td>3 (24%)</td>
<td>5 (36%)</td>
</tr>
<tr>
<td>Allele G (Gly16)</td>
<td>27%</td>
<td>23%</td>
<td>36%</td>
</tr>
<tr>
<td>Gln27Glu</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>16 (62%)</td>
<td>9 (69%)</td>
<td>6 (42%)</td>
</tr>
<tr>
<td>CG</td>
<td>6 (23%)</td>
<td>1 (7%)</td>
<td>5 (36%)</td>
</tr>
<tr>
<td>GG</td>
<td>4 (15%)</td>
<td>2 (14%)</td>
<td>3 (21%)</td>
</tr>
<tr>
<td>Allele G (Glu27)</td>
<td>27%</td>
<td>19%</td>
<td>42%</td>
</tr>
<tr>
<td>Thr164Ile</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>21 (81%)</td>
<td>13 (100%)</td>
<td>12 (92%)</td>
</tr>
<tr>
<td>CT</td>
<td>2 (8%)</td>
<td>0</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>TT</td>
<td>3 (11%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Allele T (Thr164)</td>
<td>15%</td>
<td>0%</td>
<td>4%</td>
</tr>
</tbody>
</table>

$\beta_{2}$AR, $\beta_{2}$ adrenoceptors; SNP, single-nucleotide polymorphism.

$\beta_{2}$AR genotyping. Table II shows the genotypes frequencies, alleles, and carrier states at amino acid positions 16, 27 and 164 of the $\beta_{2}$AR gene.

The distribution of expected and observed frequencies of the different genotypes at the different amino acid positions followed the Hardy-Weinberg equilibrium both in patients and controls. Minor allele frequencies in our Caucasian Spanish sample from Alicante Department of Health, General Hospital were Gly16 (allele G, 0.24-0.44), Glu27 (allele G, 0.19-0.38) and Ile164 (allele T, 0.00-0.15).

Carriage of Arg16, Gln27 and Ile164 was more prevalent in controls, OA and LC patients. Even though we observed some differences in allele frequency i.e., a higher frequency of G allele (Gly16) in LC patients, especially in responders; however, none of these differences were statistically significant probably due to the reduced sample size.

In global, subjects with any of the $\beta_{2}$AR SNPs analyzed shown a non-significant decrease in cAMP increase (mean ± SD) at isoproterenol 10^{-5} mM vs. wild type (WT) (Fig. 2): In controls (94±70 vs. 85±64 pmol/ml/10^6 cells, P=0.753), OA (52±31 vs. 34±19 pmol/ml/10^6 cells, P=0.054) and LC patients (15±17 vs. 13±16 pmol/ml/10^6 cells, P=0.718) (Fig. 3A). The prevalence of the different genotypes did not differed between patients according to any clinical variable in both models of chronic inflammation (Fig. 3B and C).

Combination of Arg16^-Gln27^ showed a decreased cAMP increase stimulus in controls (n=5), OA (n=13) and cirrhotic (n=6) (50±32, 38±21 and 14±19 pmol/ml/10^6 cells, respectively, P=0.094) (data not shown). The bigger decrease AC stimulus was evidenced for the Arg16^-Gln27^ in controls (48% $\beta_{2}$AR agonism stimulus blocked) and for Arg16^-Gln27^ in OA (51% agonism stimulus blocked). In cirrhotic (13% agonism stimulus blocked) the stimulus was the same for both Arg16^-Gln27^ or Arg16^-Gln27^.

$\beta_{2}$AR expression. Western blot detection of $\beta_{2}$AR showed a decreased expression above 0.411-fold for OA and 0.845-fold for LC compared to healthy controls (data not shown).

Discussion

In this study we showed that the functional activity of PBMC $\beta_{2}$AR from patients with different types of chronic
inflammatory diseases (OA and LC) was significantly decreased in comparison with healthy volunteers. According to severity of diseases, OA patients receptor showed a higher loss of functionality in KL grade 4 and knee joint replacement. However, in LC patients there was no significant relation between β2AR functionality and severity of disease. These differences were not related to the β2AR genotype analyzed.

We evaluated mononuclear cell β2AR responsiveness to isoproterenol to test the hypothesis that patients with chronic inflammatory diseases have a β2AR abnormality. In basal conditions (no pharmacologic stimulation of the receptor), intracellular cAMP levels showed no significant difference between OA and LC patients and controls. However, the response to β2AR stimulation with an agonist was significantly lower in patients. At high isoproterenol concentrations (10⁻⁵ M) AC activation response were a 50 and 85% lower than controls in OA and LC patients, respectively. These findings suggest that β2AR function itself is disturbed in patients...
with chronic inflammatory diseases. These blunted cAMP responses could be mainly caused by a decrease in receptor density (downregulation) (47) and/or by functional uncoupling (desensitization) (48,49). Some studies suggested that β2AR responsiveness decreases with age subsequently decreasing β2AR function (50). No significant differences for age were found between controls and LC patients that could explained the differences in β2AR responsiveness. However, OA is an age-related disorder and OA patients in our study were significantly older than control and LC groups, we could not discard that differences in β2AR function are due to the advanced age in OA individuals, so further studies with age matched controls should be performed.

Previous studies showed that β2AR density and increase in intracellular cAMP levels in response to stimulation were decreased on PBMC in patients with chronic joint diseases (51,52). Wahle et al (53) showed a reduction of β2AR densities on B lymphocytes mirrored by an impaired intracellular cAMP generation in patients with chronic rheumatic diseases (RA, systemic lupus erythematosus, and systemic sclerosis) and chronic muscle pain disorders such as fibromyalgia and regional myofascial pain (48,54,55). It is not clear whether this phenomenon occurs in response to the inflammatory process or precedes exacerbations of chronic rheumatic diseases. According to this, in our study, receptor levels were decreased above 41% for OA and 85% for LC compared to healthy standard, in a similar way that percentage of receptor agonism stimulus reduction.

Agonist binding to the β2AR causes the receptor to interact with and activate G-protein, which in turns activates AC. AC catalyzes the conversion of adenosine triphosphate (ATP) to cAMP activating dependent protein kinase. This results in phosphorylation of particular proteins and specific actions that depend on the cells and tissue (56). Then continuous stimulation of β2AR on PBMC, by elevated circulating catecholamine, may trigger a sympathetic adaptive mechanism.

Animal studies indicated that prior elevation of adrenaline and repeated stress down-regulate sympathetic responses to new stress, whereas prior exposure to β2AR agonist and intensive exercise reduce beta-adrenergic sensitivity (57,58). Norepinephrine is released locally from sympathetic nerve terminals in synapse like junctions with immune cells and could exert down regulatory autocrine effects counteracting the chronicity of the disease in the inflamed joint synovium (59), determining for example, the disease onset, progression, and severity in RA and OA (1,11-13). In the chronic phase of RA, the SNS has a strong anti-inflammatory role, reducing both bone destruction and inflammation in RA (60). Very similar effects were described in two models of chronic inflammatory bowel disease as Cohn's disease and diverticulitis (61).

Our data shows that patients with cirrhosis, varices and clinical decompensation had a reduced β2AR signalling in PBMC, suggesting the existence of changes of this cellular signalling pathway associated to the progression of this pathology. New studies with higher sample size are needed to clarify if this phenomenon could be considered as a molecular biomarker.

In our study, impairment of β2AR occurs in an independent way of the genetic profile. β2AR decreased functionality is not correlated to the presence of any SNP analyzed. A number of polymorphisms of the β2AR have been described that appear to alter the behaviour of the receptor following agonist exposure. These include Arg16Gly, Glu27Gln, and Thr164Le. Our sample has an Arg16 and Glu27 similar frequency to those showed in different Caucasian populations (Arg16 (0.38-0.46), Glu27 (0.35-0.46) and Ile164 (0.02-0.40)) (62,85).

Presence of Glu27 (allele G) is associated with a decreased agonist-promoter down-regulation, less receptor desensitization being more sensitive to endogenous catecholamine and showing a greater susceptibility to stress-induced augmentation of visceral and somatic sensory function. On the contrary Gly16 (allele G) showed an increased receptor desensitization and Ile164 (allele T) a decreased affinity agonist binding (64,65). In this way, previous results have shown that SNPs at Arg16 ‘-Glu27’ can modulated disease activity in RA, asthma and myasthenia gravis (38,66,67). In our sample, severity of disease was not associated with any particular genotype. Subjects (OA and controls) with sustained ability to cAMP reacted to isoproterenol stimulus evidencing the highest cAMP blockade for the Gln27. Other studies in asthma had shown that Glu27 avoid downregulation and thus, it was associated with less reactive airways (68).

The Gly16 receptor variant downregulates to a greater extent and is associated with increased airway hyperactivity and greater susceptibility to stress-induced augmentation of visceral and somatic sensory function, compared with those homozygous for Arg16 (39). The receptors homozygous for Ile164 had markedly decreased ligand binding and coupling properties compared with those homozygous for Thr164. However, an individual can be homozygous or heterozygous for given polymorphisms, and large populations will have to be analysed to determine their importance on clinical phenotypes (69).

Although the amount of adrenergic receptor on lymphocytes has been shown to be related to the number of adrenergic receptors on heart tissue (70), future studies should employ a more direct assessment on liver and joint. A definitive evaluation of the relationship between the effects of β2AR polymorphism and functionality requires large prospective multicenter trials to enable simultaneous consideration of single and multiple genotypes.

In conclusion, decreased β2AR functionality in patients with OA and LC was independent of patient’s β2AR genotype.

Acknowledgements

We would like to thank to Paula Giménez Martínez from the CIBERehd for her technical support with the EIA and cell culture and Bioiberica (Barcelona) for the financial support to develop this project.

References


